Open AccessAnti-viral Immunity in the Tumor Microenvironment: Implications for the Rational Design of Herpes Simplex Virus Type 1 Oncolytic Virotherapy
Author(s) -
Paul J. F. Rider,
Ifeanyi K. Uche,
Larissa Sweeny,
Konstantin G. Kousoulas
Publication year - 2019
Publication title -
current clinical microbiology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.657
H-Index - 16
ISSN - 2196-5471
DOI - 10.1007/s40588-019-00134-3
Subject(s) - oncolytic virus , herpes simplex virus , virotherapy , tumor microenvironment , immunosuppression , biology , virology , immunology , virus , cancer research , immune system
The design of novel herpes simplex type I (HSV-1)-derived oncolytic virotherapies is a balancing act between safety, immunogenicity and replicative potential. We have undertaken this review to better understand how these considerations can be incorporated into rational approaches to the design of novel herpesvirus oncolytic virotherapies.